Surgify Medical, an Espoo-based MedTech firm centered on enhancing the protection and precision of bone surgical procedure with its Surgify Halo know-how, has efficiently raised €7 million in Sequence A funding.
The funding spherical was led by ZEISS Ventures, the company enterprise arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s present buyers, together with Lednil and Cascara Ventures, additionally participated within the financing.
“ZEISS brings unparalleled expertise in surgical know-how and a world community, whereas the EIC’s continued assist and earlier grant financing underscore the European innovation ecosystem’s confidence in our resolution,” stated Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in each the EU and the U.S., we’re well-positioned to deliver our distinctive know-how to extra surgeons and sufferers internationally.”
Based in 2017, Surgify Medical is devoted to innovating bone surgical procedure by making it safer, quicker, and extra exact. The corporate’s flagship product, Surgify Halo, is designed to distinguish between exhausting and gentle tissues, reportedly offering enhanced safety towards incidental gentle tissue harm and streamlining procedures.
The advantages of Surgify Halo prolong past its core market of head, neck, and backbone surgical procedures. Surgify’s know-how additionally has the potential to affect the rising subject of robotic surgical procedure by enabling dependable automated bone resection.
With the funding, the corporate plans to take the following steps towards turning into a number one provider within the multi-billion-euro marketplace for bone surgical procedure gadgets. Constructing on a profitable Nordic market launch, the corporate will increase its operations within the EU and america, the place Surgify says key hospitals have already began adopting the know-how.
“Surgify’s know-how is a significant breakthrough in at the moment’s evolving healthcare panorama. With over a thousand affected person procedures, Surgify Halo has already left a major footprint within the subject. The corporate goals to guard sufferers, save prices, and has already achieved groundbreaking developments in robotic surgical procedure functions,” stated Alan Raffensperger, Chairman of Surgify Medical.
In response to the corporate, standard surgical drills spin tens of 1000’s of occasions per minute and will be harmful if they arrive into contact with essential gentle tissue. At worst, such gentle tissue harm may end up in extreme damage to the affected person. Comfortable tissue accidents are thought-about a extremely related surgical complication in lots of sorts of head, neck, and backbone procedures involving bone resection and lead to over €4 billion in annual complication-related prices globally.
Surgify Halo reportedly cuts bone whereas offering distinctive protecting capabilities towards incidental accidents to gentle tissues equivalent to central nervous system constructions, blood vessels, and nerves. The know-how is claimed to offer efficient bone resection together with a gentle tissue safety characteristic for enhanced security and precision in surgical procedures.
“We’re excited to companion with Surgify of their mission to determine a brand new benchmark for surgical security. Surgify’s Halo burrs provide distinctive management at chopping charges corresponding to conventional burrs, whereas concurrently safeguarding delicate gentle tissues. This makes the change to Halo burrs an apparent alternative for surgeons,” explains Dr Boris Hofmann, Head of ZEISS Ventures. “We’re desperate to assist the staff as they increase their resolution on a world scale.”
So far, Surgify Medical has raised €14 million in complete funding and has workplaces in Finland, Sweden, Denmark and america.
